Search

Your search keyword '"Mohseni, Rashin"' showing total 43 results
Start Over Author "Mohseni, Rashin"
43 results on '"Mohseni, Rashin"'

9. Posterior Reversible Encephalopathy Syndrome in Pediatric Hematopoietic Stem Cell Transplantation with Beta Major Thalassemia: The Association between the PRES Occurrence and Class of Beta Major Thalassemia

Author

Jafari, Leila, primary, Behfar, Maryam, additional, Tabatabaie, Soroor, additional, Karamlou, Yalda, additional, Kashani, Homa, additional, Radmard, Amir Reza, additional, Mohseni, Rashin, additional, Naji, Parisa, additional, Ghanbari, Fatemeh, additional, Ashkevari, Pooya, additional, Fakhr, Hoda, additional, Mohammadi, Shiva, additional, and Hamidieh, Amir Ali, additional

Published
2023
Full Text
View/download PDF

11. Posterior Reversible Encephalopathy Syndrome in Pediatric Hematopoietic Stem Cell Transplantation with Beta Major Thalassemia: The Association between the PRES Occurrence and Class of Beta Major Thalassemia.

Author

Jafari, Leila, Behfar, Maryam, Tabatabaie, Soroor, Karamlou, Yalda, Kashani, Homa, Radmard, Amir Reza, Mohseni, Rashin, Naji, Parisa, Ghanbari, Fatemeh, Ashkevari, Pooya, Fakhr, Hoda, Mohammadi, Shiva, and Hamidieh, Amir Ali

Subjects
POSTERIOR leukoencephalopathy syndrome, STEM cell transplantation, BETA-Thalassemia, HEMATOPOIETIC stem cell transplantation, HEPATIC veno-occlusive disease, SYNDROMES in children, PANCREATIC beta cells, CHILD patients
Abstract

Introduction: Allogeneic hematopoietic stem cell transplantation (HSCT) is the only definitive curative option for β‐major thalassemia patients (β‐MT). Posterior reversible encephalopathy syndrome (PRES) is a pervasive neurological complication which typically occurs following HSCT. β‐MT patients are prone to a higher PRES incidence due to long‐term immunosuppression; thus, it is imperative that these patients are closely monitored for PRES after HSCT. Patients and methods: We included 148 pediatric patients with β‐MT who underwent HSCT between March 2015 and August 2022 in Children's Medical Center. Patients in this study were divided into two groups. The association between PRES and class of β‐MT and other risk factors were assessed and the overall survival rate was determined. Results: Fourteen out of 112 patients (12%) with class I and II β‐MT developed PRES. However, PRES occurred in 11 out of 36 patients (30.5%) with β‐MT‐III. Our results indicated that there was a significant association between class III β‐MT and the occurrence of (P =.004). Additionally, acute graft‐versus‐host disease (aGVHD) occurred in 80% and 44.7% of patients in the PRES and non‐PRES groups, respectively (P =.001). The results of the Kaplan‐Meier analysis revealed that the 5‐year overall survival (OS) was 75.6% in the PRES group versus 95% in the non‐PRES group, which was statistically significant (P =.001). Conclusion: Based on our results, pediatric β‐MT III patients are at a higher risk of developing PRES. Additionally, pediatric β‐MT patients with a history of aGVHD, regardless of disease class, are more likely to develop PRES. Considering these results, PRES has a higher chance of being the etiology of symptoms and should be considered more often in these patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. The Outcome of Extracorporeal Photopheresis Using Cryopreservation in Pediatric Patients with Acute and Chronic Gvhd at the Largest Children’s Medical Hospital in Iran

Author

Hamidieh, Amir Ali, primary, Jafari, Leila, additional, Delkhah, Mona, additional, Asefi, Nika, additional, Karamlou, Yalda, additional, Mohseni, Rashin, additional, Jafari, Fahimeh, additional, Nikfetrat, Zeynab, additional, Farajifard, Hamid, additional, and Behfar, Maryam, additional

Published
2023
Full Text
View/download PDF

16. The Safety and Feasibility of Intra Surgical Cavity or intra Cerebrospinal Fluid (CSF) Injection of Haploidentical Activated NK Cells in Patients with Recurrent Glioblastoma Multiforme and Brain Tumors

Author

Asl, Niloufar Shayan, primary, Behfar, Maryam, additional, Amiri, Rouzbeh Shams, additional, Mohseni, Rashin, additional, Azimi, Masoumeh, additional, Jafari, Yalda, additional, Faranoush, Mohammad, additional, Izadpanah, Amirhossein, additional, Mohammad, Monireh, additional, Hamidieh, Amir Ali, additional, Habibi, Zohreh, additional, and Ebrahimi, Marzieh, additional

Published
2022
Full Text
View/download PDF

25. An open-label phase 1 clinical trial of the allogeneic side population adipose-derived mesenchymal stem cells in SMA type 1 patients

Author

Mohseni, Rashin, primary, Hamidieh, Amir Ali, additional, Shoae-Hassani, Alireza, additional, Ghahvechi-Akbari, Masood, additional, Majma, Anahita, additional, Mohammadi, Mahmoud, additional, Nikougoftar, Mahin, additional, Shervin-Badv, Reza, additional, Ai, Jafar, additional, Montazerlotfelahi, Hadi, additional, and Ashrafi, Mahmoud Reza, additional

Published
2021
Full Text
View/download PDF

28. Clinical outcome of the Intrathecal administration of the allogeneic side population Adipose Derived Mesenchymal Stem Cells in Werdnig Hoffman patients: An open-label Phase I clinical trial

Author

Mohseni, Rashin, primary, Hamidieh, Amir Ali, additional, Shoae-Hassani, Alireza, additional, Ghahvechi-Akbari, Masood, additional, Majma, Anahita, additional, Mohammadi, Mahmoud, additional, Nikougoftar, Mahin, additional, Shervin-Badv, Reza, additional, Ai, Jafar, additional, Montazerlotfelahi, Hadi, additional, and Ashrafi, Mahmoud Reza, additional

Published
2020
Full Text
View/download PDF

43. Escalated Dose Donor Lymphocyte Infusion Treatment in Patients with Primary Immune Deficiencies After HSCT with Reduced-Intensity Conditioning Regimen.

Author

Ali T, Behfar M, Mohseni R, Salajegheh P, Kheder M, Abou-Fakher F, Nikfetrat Z, Jafari F, Naji P, and Hamidieh AA

Subjects
Male, Child, Female, Humans, Child, Preschool, Lymphocyte Transfusion, Transplantation Conditioning, Lymphocytes, Graft vs Host Disease etiology, Graft vs Host Disease prevention & control, Hematopoietic Stem Cell Transplantation adverse effects, Primary Immunodeficiency Diseases
Abstract

Objective/background: Mixed chimerism is a major concern after allogenic hematopoietic stem cell transplantation (HSCT) using a reduced-intensity conditioning (RIC) regimen in primary immunodeficiencies (PIDs). A donor lymphocyte infusion (DLI) escalating dose regimen has been developed with the aim of reducing toxicity while preserving efficacy. However, the graft-versus-host disease (GvHD) development remains the most common and adverse effect of DLI and continues to be a limiting factor in its application, especially nonmalignant diseases such as PIDs. We prospectively evaluated PID patients after HSCT using RIC in Childrens Medical Center, who were candidates for an escalating dose of DLI for MC from 2016 to 2018., Methods: With the median follow-up of 16.4 months, 12 patients (nine males and three females) with a median age of 3.72 years received DLI. The median number of DLI was 3.2 (range, 1-5), the maximum and total dose of DLIs administered per patient were 3.6 × 10 7 (range, 1-5) cells/kg CD3 + and 9.3 × 10 7 (range, 1-15) cells/kg CD3 + cells, respectively., Results: Median donor chimerism at baseline before the DLIs was 41% (range, 11-73%), patients received DLIs at a median of 105 (range, 37-230) days and 52 (range, 3-168) days after the HSCT and onset of the MC, respectively. At the final assessment, six (54.5%) patients improved after DLIs at a median of 47.3 days., Conclusion: PID patients may benefit from DLI with an escalating dose regimen, but the GvHD development remains a concern during the DLI, and the optimum dose and frequency must be standardized.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results